New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 30, 2013
10:55 EDTFDX, FDX, LLY, LLYSenate Finance Committee to hold a hearing
The Committee holds a hearing entitled, "Transatlantic Trade and Investment Partnership: Achieving the Potential". Participants include Executive Vice President Ducker of FedEx (FDX) and Senior Vice President Ricks of Eli Lilly (LLY) at the hearing being held on October 30 at 11 am. Webcast Link
News For FDX;LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 16, 2014
15:26 EDTFDXFedEx December 175 straddle priced for 3.6% movement into Q2
Subscribe for More Information
15:11 EDTFDXFedEx technical comments ahead of results
Subscribe for More Information
14:48 EDTLLYEli Lilly's CYRAMZA receives third FDA approval
Subscribe for More Information
09:45 EDTFDXFedEx provides short-term trade opportunity, says Bernstein
Subscribe for More Information
December 15, 2014
17:03 EDTFDXFedEx announces acquisition of GENCO
Subscribe for More Information
16:33 EDTLLYEli Lilly raises quarterly dividend 2% to 50c per share
Subscribe for More Information
09:24 EDTFDXFedEx says higher e-commerce purchases increases residential deliveries
Subscribe for More Information
08:53 EDTFDXFedEx December volatility increases into Q2 and outlook
Subscribe for More Information
December 12, 2014
12:52 EDTLLYEli Lilly: FDA expands approved use of Cyramza to treat lung cancer
Subscribe for More Information
December 11, 2014
14:47 EDTFDXFedEx management to meet with
Meeting to be held in Florida on December 18 hosted by William Blair.
11:07 EDTFDXFedEx December volatility increases into Q2 and outlook
Subscribe for More Information
10:13 EDTFDXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:13 EDTLLYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:40 EDTLLYEli Lilly upgraded at Morgan Stanley
As previously reported, Morgan Stanley upgraded Eli Lilly two notches to Overweight from Underweight. The firm has increased confidence in Eli Lilly's pipeline investments following recent external data in Alzheimer's and atherosclerosis and now expects potential evacetrapib peak sales of $3B and solanezumab peak sales of $10B. Price target raised to $85 from $60.
06:22 EDTLLYEli Lilly upgraded to Overweight from Underweight at Morgan Stanley
Subscribe for More Information
06:17 EDTFDXFedEx initiated with a Neutral at UBS
Subscribe for More Information
December 10, 2014
16:57 EDTFDXFedEx Freight says Teamsters withdraw election petition
Subscribe for More Information
December 9, 2014
07:44 EDTLLYAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:11 EDTLLYEli Lilly and Incyte announce Phase 3 RA-BEACON study met primary endpoint
Subscribe for More Information
December 8, 2014
08:10 EDTLLYLilly, Anthem, HealthCore form five-year research collaboration
Eli Lilly and Company (LLY), Anthem (ANTM) and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use